2017 AHA / ACC Update on 2014 Valvular Disease Q2

According to the
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease Failure” p 258

“Anticoagulation with ___________ is indicated for patients with rheumatic mitral stenosis (MS) and AF”

a) a vitamin K antagonist (VKA)
b) a direct oral anticoagulant (DOAC)
c) a vitamin K antagonist (VKA) or a direct oral anticoagulant (DOAC)
d) a vitamin K antagonist (VKA) or a direct oral anticoagulant (DOAC) in addition to low dose aspirin (75-100 mg daily)

click here for answer

(A)  

“Anticoagulation with a vitamin K antagonist (VKA) is
indicated for patients with rheumatic mitral stenosis
(MS) and AF”

Leave Comment

Your email address will not be published. Required fields are marked *